EUVIMEDEUVIMED entdecken
Crossref

Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists

Myfanwy Jenkins iD, Nicola Watson, Margaret McPhee, Nick J Levell iD, Mike Arden-Jones iD, Anthony D Ormerod, Philip J Hampton

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Myfanwy Jenkins und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Pyoderma Gangrenosum, Practice Patterns, Physicians', Biological Products, Prednisolone. Die Arbeit nennt 8 Literaturangaben. Gefördert von: The, was, UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyoderma gangrenosum (PG) is an ulcerative inflammatory disorder affecting the lower legs in 80% of patients. The use of biologic medications to treat PG is increasing, although there is a limited evidence base to guide treatment choices. In some health systems, such as the UK National Health Service, limitations are placed on biologic prescribing for PG, leading to wide variations in prescribing. A survey of mainly UK clinicians showed that prednisolone remains the first-line treatment for PG (90%, 34/38). Biologics have been used by 66% (25/38) of clinicians as second-line therapy, but 19% (7/38) have had prescribing requests declined. Further research is needed to determine optimal treatment strategies for PG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pyoderma GangrenosumPractice Patterns, Physicians'Biological ProductsPrednisoloneHumansUnited KingdomSurveys and QuestionnairesHealth Services AccessibilityDermatologyDermatologists

Substanzen

Biological ProductsPrednisolone

Autor:innen und Institutionen

  • Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Department of Dermatology, University of Nottingham, Nottingham, UK.
  • Department of Dermatology, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK.
  • Department of Dermatology, University of Southampton Faculty of Medicine, Southampton, UK.
  • University of Aberdeen, Aberdeen, UK.
  • Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.

ORCID-Profile: Myfanwy Jenkins, Nick J Levell, Mike Arden-Jones

Förderung

  • The
  • was
  • UK
  • British Association of Dermatologists
  • University of Nottingham

Zitieren

APA

Jenkins, M., Watson, N., McPhee, M., Levell, N. J., Arden-Jones, M., D Ormerod, A., & Hampton, P. J. (2024). Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae153

Vancouver

Jenkins M, Watson N, McPhee M, Levell NJ, Arden-Jones M, D Ormerod A, et al. Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae153

BibTeX
@article{Jenkins2024,
  author = {Jenkins, Myfanwy and Watson, Nicola and McPhee, Margaret and Levell, Nick J and Arden-Jones, Mike and D Ormerod, Anthony and Hampton, Philip J},
  title = {Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae153}
}
Kostenlos starten →